References
- Makoni SN. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and a review of the literature. Heart 2001;86:E18. https://doi.org/10.1136/heart.86.6.e18
- Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-80. https://doi.org/10.1161/01.CIR.92.9.2373
- Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61. https://doi.org/10.1056/NEJM199404073301402
- Lincoff AM, Mark DB, Tcheng JE, et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 2000;102:2923-9. https://doi.org/10.1161/01.CIR.102.24.2923
- EPISTENT Investigators. Randomised placebo-controlled and balloonangioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92. https://doi.org/10.1016/S0140-6736(98)85010-1
- Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109:2203-6. https://doi.org/10.1161/01.CIR.0000127867.41621.85
- Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121:535-55. https://doi.org/10.1046/j.1365-2141.2003.04334.x
- Claeys LG, Berg W. Major bleeding and severe thrombocytopenia after combined heparin and abciximab-c7E3 Fab therapy. Eur J Vasc Endovasc Surg 2003;25:85-7. https://doi.org/10.1053/ejvs.2002.1757
- Klein LW, Kern MJ, Berger P, et al. Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2003;60:194-201. https://doi.org/10.1002/ccd.10620
- Butler MJ, Chan W, Taylor AJ, Dart AM, Duffy SJ. Management of the no-reflow phenomenon. Pharmacol Ther 2011;132:72-85. https://doi.org/10.1016/j.pharmthera.2011.05.010
- Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-82. https://doi.org/10.1016/S0002-9149(99)80410-X
Cited by
- Abciximab : Acute profound thrombocytopenia in an elderly patient: case report vol.1482, pp.1, 2013, https://doi.org/10.1007/s40278-013-7693-3